Head-to-head · WeighScore
Edessa vs Zera Health
By GLP-1 ScorecardUpdated
Score comparison
Zera Health has the higher recorded score — 74.8/100 to 70.8/100.
Zera Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Zera lists separate first-month, monthly and quarterly prices for its compounded GLP-1 programs.
Before you choose
Before comparing the headline prices, the Edessa review and the Zera Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, AZ Health vs Edessa and Henry Meds vs Zera Health compare each of them with another graded program, and the list of alternatives to Edessa ranks the programs closest to Edessa on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Collective review covers one graded close to these two, at 71.6/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Edessa | Zera Health |
|---|---|---|
| WeighScore | 70.8/100 | 74.8/100 |
| Grade | C | C |
| Site position | #110 | #63 |
| Semaglutide | $179/mo month-to-month injectable ($135 only on a 6-month prepay) | $179/mo (advertised monthly compounded plan) |
| Tirzepatide | $239/mo month-to-month ($209 only on a 6-month prepay) | $255/mo (advertised monthly compounded plan) |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Strengths
- Each product page carries a plain three-rung table, so the commitment behind every figure is visible
- "Same price, every dose" is printed on each product page
- Names its operating entity and a full street address in Las Vegas, Nevada
- All-inclusive: provider consultation, medication, free expedited shipping, ongoing check-ins and 24/7 clinical support, and HSA and FSA eligible
- An oral tablet sits beside the two injections
What to consider
- The homepage leads with "Start for just $135", a six-month prepay on the semaglutide injection; month-to-month tirzepatide is $239
- All three homepage cards quote the six-month rung, so the real monthly rates appear only after a click
- Its Terms give two corporate forms for the same company in one clause — "Edessa Group, LLC, a Nevada corporation"
- "Join 100,000+ successful GLP-1 patients" carries no source, and the money-back guarantee's terms are on no marketing page
- No lab or monitoring protocol is published
Strengths
- Publishes distinct monthly and quarterly price displays
- The product pages describe shipping, physician oversight and support as included
What to consider
- The first-month headlines do not establish renewal prices
- The written policy requires 72 hours’ notice before billing to stop the next charge
- Ask which charges would be refundable if you are disqualified
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.